Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - By Drug Class, Symptoms, causes, diagnosis, treatment, and risk factors, Opportunity Analysis, 2021 – 2026

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis

Overview

Chronic obstructive pulmonary disease (COPD) is a condition in which the lungs become inflamed, obstructing airflow. It is a long-term illness with symptoms such as trouble breathing, mucus production, wheezing, and others. COPD (chronic bronchitis, emphysema, and refractory asthma) is a progressive lung illness that encompasses chronic bronchitis, cirrhosis, and refractory asthma. Nicotine, carbon emissions, respiratory problems, alpha-1 deficiency-related emphysema (a rare type of COPD), and other factors are among the leading causes of chronic obstructive pulmonary disease. Complications can be avoided and illness development can be delayed in some methods. Quitting smoking, taking prescribed medications, and avoiding related co-morbidities like the flu, pneumonia, and other infections by being vaccinated against them are just a few examples.

Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2656

Drivers

Over the forecast period, the high incidence and prevalence of chronic obstructive pulmonary disease (COPD), together with individual organization awareness initiatives, is projected to stimulate the global chronic obstructive pulmonary disease (COPD) treatment market expansion. Chronic obstructive pulmonary disease (COPD) was the third greatest cause of mortality worldwide in 2016, as per the National Center for Biotechnology Information (NCBI). COPD was also widespread in over 300 million individuals worldwide in 2013, according to the Global Burden of Disease Study. Furthermore, according to the same source, the occurrence of COPD in European individuals over 40 years of age varied from 15-20 percent in 2016. Furthermore, the World Health Organization (WHO) says that in 2016, there were 251 million cases of COPD worldwide, as per the Global Burden of Disease Study.

Over the forecast period, rising prevalence is projected to drive growth in the global chronic obstructive pulmonary disease (COPD) treatment market. The World Health Organization (WHO), the COPD Foundation, the American Thoracic Society, and the Centers for Disease Control and Prevention (CDC) all endeavor to raise public awareness of COPD. The National Institutes of Health (NIH) has a campaign called "COPD Learn More Breathe Better," and November is designated as COPD Awareness Month. Over the forecast period, these factors are projected to propel the global chronic obstructive pulmonary disease (COPD) treatment market expansion.

Tailored Information as per niche requirement:

LIMITED TIME OFFER - Hurry Up!

Exclusive offer!!! Purchase the report at a discounted rate!!!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2656

In 2017, the global chronic obstructive pulmonary disease (COPD) treatment market was worth US$ 14,209.0 million, and it is estimated to grow at a healthy CAGR of 4.9 percent from 2018 to 2026.

The global chronic obstructive pulmonary disease (COPD) treatment market is positioned to gain from ongoing research & development as well as new product introductions.

In May of this year, Verona Pharma began a phase IIb clinical study to evaluate nebulized ensifentrine (RPL554) in conjunction with a long-acting bronchodilator for the treatment of moderate to severe COPD. In March 2019, Novartis AG released Ultibro Breezhaler and Seebri Breezhaler in China to treat COPD. In April 2019, Cipla released Niveoli, a beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for individuals with obstructive airway disorders (OADs) such as asthma and COPD.

Furthermore, through offering surgical devices, web-based apps, and other attempts to lower the worldwide burden of chronic obstructive pulmonary disease, producers are contributing to the overall COPD treatment paradigm. In May 2019, Spire Health announced the start of a research project to create new digital biomarkers that might predict exacerbations—and even hospitalizations—in patients with severe COPD. Over the forecast period, these factors are projected to boost the global chronic obstructive pulmonary disease (COPD) treatment market expansion.

Restraints

Although, developing new medications is a difficult undertaking, and medication failures in clinical trials have hampered market expansion. In May 2019, the asthma medicine benralizumab failed to reduce yearly COPD exacerbation rates in individuals with mild to severe COPD. GALATHEA and TERRANOVA were Phase III, randomized, double-blind, placebo-controlled, parallel-group clinical studies that looked at the effectiveness and safety of benralizumab in the treatment of moderate to severe COPD patients.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/global-chronic-obstructive-pulmonary-disease-copd-treatment-market-to-surpass-us-218-billion-threshold-by-2026-1411

Competitive Landscape

Key companies contributing in the global chronic obstructive pulmonary disease (COPD) treatment market are Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Mylan N.V., AstraZeneca Plc, CHIESI Farmaceutici SpA, Orion Corporation, Sunovion Pharmaceuticals, Inc., Novartis AG, and GlaxoSmithKline plc.

Table of Contents

1. Research Objective and assumption
• Research Objectives
• Assumptions
• Abbreviations
2. Market Purview
• Report Description
• Market Definition and Scope
• Executive Summary
• Market Snippet, By Drug Class
• Market Snippet, By Route of Administration
• Market Snippet, By Distribution Channel
• Market Snippet, By Region
• Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
• Market Dynamics
• Drivers
• Restraints
• Market Opportunities
• Regulatory Scenario
• Key Highlights
• Research and Development Collaboration, Mergers, and Acquisitions
• PEST Analysis
• Pipeline Analysis
• Epidemiology
4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2016–2026 (US$ Mn)
• Introduction
• Market Share Analysis, 2017 and 2026 (%)
• Y-o-Y Growth Analysis, 2018–2026
• Segment Trends
• Bronchodilators
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
• Beta 2-Agonists
• Anticholinergics
• Theophyllines
• Phosphodiesterase Type 4 Inhibitors
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
• Steroids
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
• Others
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration, 2016–2026 (US$ Mn)
• Introduction
• Market Share Analysis, 2017 and 2026 (%)
• Y-o-Y Growth Analysis, 2018–2026
• Segment Trends
• Oral
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
• Inhalation
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2016–2026 (US$ Mn)
• Introduction
• Market Share Analysis, 2017 and 2026 (%)
• Y-o-Y Growth Analysis, 2018–2026
• Segment Trends
• Hospital Pharmacies
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
• Retail Pharmacies
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
• Online Pharmacies
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Regions, 2016–2026 (US$ Mn)
• Introduction
• Market Share Analysis, By Region, 2017 and 2026 (%)
• Y-o-Y Growth Analysis, For Regions, 2018–2026
• North America
• Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
• U.S.
• Canada
• Europe
• Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of APAC
• Latin America
• Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Africa
• Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Country/Region, 2016–2026 (US$ Mn)
• Central Africa
• South Africa
• North Africa
• Middle East
• Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
• Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
• GCC
• Israel
• Rest of Middle East
8. Competitive Landscape
• Heat Map Analysis
• Company Profiles
• AstraZeneca Plc
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Orion Corporation
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Mylan N.V.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Boehringer Ingelheim
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Teva Pharmaceutical Industries Ltd.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• GlaxoSmithKline plc
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Novartis AG
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• Sunovion Pharmaceuticals, Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
• CHIESI Farmaceutici SpA
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
9. Section
• References
• Research Methodology
• About us and Sales Contact

Other Related Reports:

Urea Cycle Disorders Treatment Market To Surpass US$ 1,510.2 Million By 2027

Stargardt Disease Therapeutics Market To Surpass US$ 1,701.0 Million By 2028

U.S Intravenous Solution Market To Surpass US$ 4,283.4 Million By 2028

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837